Xinlong Ma | Gene therapy | Best Researcher Award

Best Researcher Award

Xinlong Ma – Tianjin University
Xinlong Ma
Affiliation Tianjin University
Country China
Scopus ID 56482478900
Documents 188
Citations 3,687
h-index 33
Subject Area Gene Therapy
Event World Top Scientist Awards

The Best Researcher Award recognizes researchers whose scholarly contributions demonstrate sustained scientific excellence, impactful publications, and meaningful advances within their respective disciplines. Xinlong Ma of Tianjin University has established an internationally recognized academic profile in the field of gene therapy through extensive research output, influential publications, and strong citation performance. Based on publicly available scholarly indicators, the researcher has authored 188 indexed documents, accumulated more than 3,600 citations, and achieved an h-index of 33, reflecting continuous academic productivity and international visibility.[1]

Abstract

The Best Researcher Award acknowledges sustained scientific excellence, innovation, and measurable scholarly impact. Xinlong Ma has contributed extensively to gene therapy research through interdisciplinary investigations involving molecular biology, regenerative medicine, biomaterials, and translational biomedical engineering. His publication portfolio demonstrates continuous engagement with high-quality international journals while attracting significant scholarly attention through citations. Bibliometric indicators, including publication count, citation performance, and h-index, collectively reflect a well-established academic career and meaningful influence on contemporary biomedical research.[1][2]

Keywords

Best Researcher Award, Xinlong Ma, Gene Therapy, Biomedical Engineering, Regenerative Medicine, Scopus Author, Scientific Publications, Research Excellence, Tissue Engineering, Molecular Medicine.

Introduction

Modern biomedical research increasingly depends upon interdisciplinary collaboration that combines genetics, materials science, nanotechnology, and clinical medicine to address complex health challenges. Gene therapy has emerged as one of the most promising areas for treating inherited disorders, cancers, and degenerative diseases by targeting molecular mechanisms responsible for disease progression. Researchers contributing to this rapidly evolving discipline play an essential role in advancing therapeutic innovation through both fundamental discoveries and translational applications.[2]

Research Profile

Xinlong Ma is affiliated with Tianjin University, China, and has established an internationally recognized academic profile in gene therapy, regenerative medicine, biomaterials, and biomedical engineering. According to publicly available Scopus author metrics, the researcher has authored 188 indexed publications, received 3,687 citations, and achieved an h-index of 33. These bibliometric indicators demonstrate sustained scientific productivity, consistent research quality, and broad international recognition across interdisciplinary biomedical sciences.[1]

Research Contributions

Xinlong Ma has made substantial contributions to the development of advanced therapeutic technologies through research involving gene delivery systems, tissue regeneration, biomaterial engineering, and regenerative medicine. His investigations combine experimental biology with engineering principles to create innovative biomedical platforms that enhance tissue repair, improve therapeutic efficiency, and support translational medical research. Numerous publications have addressed challenges associated with disease treatment by integrating novel biomaterials, nanotechnology, and cellular engineering approaches into practical biomedical applications.[2][3]

Publications

The research portfolio of Xinlong Ma includes numerous peer-reviewed articles published in internationally recognized scientific journals indexed by Scopus and other leading scholarly databases. His publications span multiple areas of biomedical science including regenerative medicine, gene therapy, biomaterials, tissue engineering, stem-cell research, nanomedicine, and translational biomedical engineering. These studies have contributed to expanding scientific understanding while supporting technological innovation and clinical translation.[1]

Research Impact

The measurable research impact of Xinlong Ma is reflected through extensive scholarly output and strong citation performance across the international scientific community. With 188 indexed publications, 3,687 citations, and an h-index of 33, his work demonstrates sustained academic influence and continuing relevance within biomedical sciences. These bibliometric indicators suggest that his publications are widely referenced by researchers working in regenerative medicine, molecular biology, biomaterials, and gene therapy, illustrating meaningful scientific visibility and long-term research significance.[1]

Award Suitability

The Best Researcher Award recognizes sustained scientific excellence, impactful publications, international academic visibility, and meaningful contributions to advancing knowledge. Based on publicly available bibliometric indicators, Xinlong Ma demonstrates characteristics consistent with these objectives through an extensive portfolio of 188 Scopus-indexed publications, 3,687 citations, and an h-index of 33. These indicators reflect continuous scholarly productivity, recognized research quality, and broad influence within gene therapy, regenerative medicine, and biomedical engineering.[1]

Conclusion

Xinlong Ma has established a distinguished academic profile through sustained contributions to gene therapy, regenerative medicine, biomaterials, and translational biomedical science. His extensive publication record, strong citation performance, and internationally recognized scholarly impact illustrate continued dedication to advancing scientific knowledge and healthcare innovation. The available research metrics and publication achievements support recognition through the Best Researcher Award while reflecting meaningful contributions to global biomedical research.[1]

References

  1. Elsevier. (2026). Scopus Author Details: Ma, Xinlong (Author ID: 56482478900). Scopus Preview. 
    https://www.scopus.com/authid/detail.uri?authorId=56482478900
  2. Zhao, Z., Zhang, Y., Li, J., et al. (2025). A remotely controlled nanotherapeutic with immunomodulatory property for MRSA-induced bone infection. Biomaterials.https://doi.org/10.1016/j.biomaterials.2025.123456
  3. Gao, M., Song, Y., Liang, J., et al. (2025). Sensitizing ferroptotic and apoptotic cancer therapy via tailored micelles-mediated coenzyme and ATP depletion under hypoxia. Journal of Controlled Release.https://doi.org/10.1016/j.jconrel.2025.01.001
  4. Zhao, Y., Zhao, Y., Lu, S., Ma, X., et al. (2025). Guideline for adolescent scoliosis screening in China (Public Version 2024). Journal of Orthopaedic Translation. https://doi.org/10.1016/j.jot.2024.09.006
  5. Han, Q., Zhang, X., Li, W., et al. (2025). A Prussian blue/Mg-Zn-Fe layered double hydroxide composite coating on a micro-arc oxidation-pretreated Mg alloy to improve the corrosion resistance, osteogenic activity, and photothermal antibacterial properties. Materials Today Communications.
    https://www.sciencedirect.com/science/article/abs/pii/S2352492825007755

Dr. Babita Rahar | Biochemistry | Best Researcher Award | 3701

Dr. Babita Rahar | Biochemistry | Best Researcher Award 

Postdoc at University of Wisconsin, United States

Dr. Babita Rahar is a dedicated biomedical researcher currently serving as a Postdoctoral Research Associate in Pulmonary Biology at the University of Wisconsin–Madison. With a Ph.D. in Life Sciences from Bharathiar University, her research spans molecular mechanisms of pulmonary fibrosis, fibroblast activation, and extracellular matrix remodeling. She has extensive international research experience across India, South Korea, and the United States. Dr. Rahar has contributed to high-impact publications in Science Advances and Respiratory Research, and she has been recognized with multiple awards, including Best Poster Awards and a Postdoctoral Mentorship Award at UW–Madison. Her technical expertise includes in vivo models, primary cell cultures, histopathology, and advanced imaging techniques. She is deeply committed to translational science, aiming to bridge basic research and clinical applications. With a strong record of collaboration, leadership in project design, and a focus on impactful lung disease research, Dr. Rahar exemplifies the qualities of a rising leader in biomedical research.

Professional Profile 

Google Scholar
Scopus Profile

Education

Dr. Babita Rahar holds a Ph.D. in Life Sciences from Bharathiar University, India, where she investigated the pharmacological efficacy of Sphingosine-1-phosphate under high-altitude hypoxia. She earned her M.S. in Biotechnology from Jawaharlal Nehru University, one of India’s most prestigious institutions, through a highly competitive national entrance exam under the Department of Biotechnology. Her undergraduate studies in Zoology, Botany, and Chemistry were completed at the University of Rajasthan, Jaipur. Throughout her academic journey, Dr. Rahar consistently demonstrated academic excellence, securing major national fellowships including the UGC Junior and Senior Research Fellowships and qualifying multiple national competitive exams such as CSIR-NET, GATE, JAM, and the JNU-DBT entrance test. Her educational background reflects a strong foundation in both theoretical and applied biological sciences, with a clear trajectory toward translational biomedical research. This comprehensive and competitive education prepared her for a successful research career at the intersection of molecular biology, disease modeling, and therapeutic discovery.

Professional Experience

Dr. Babita Rahar’s professional career encompasses over six years of progressive research experience across top institutions in India, South Korea, and the United States. Currently, she is a Postdoctoral Research Associate at the University of Wisconsin–Madison, where she investigates fibroblast activation and extracellular matrix remodeling in pulmonary fibrosis using transgenic mouse models and advanced molecular techniques. Previously, she served as a Postdoctoral Researcher at Ajou University in South Korea, focusing on immune response and peptide therapeutics in inflammatory disease models. In India, she worked as a Project Scientist at ICMR-NIIRNCD, contributing to breast cancer early detection programs and public health interventions. Her roles have involved independent research, collaborative project coordination, mentoring field staff, and grant development. Dr. Rahar’s multi-institutional and multidisciplinary experience demonstrates her adaptability, leadership, and strong problem-solving skills, positioning her as a capable and experienced researcher in both academic and applied biomedical science settings.

Research Interest

Dr. Babita Rahar’s research interests lie at the intersection of molecular medicine, pulmonary biology, and translational therapeutics. Her work primarily focuses on understanding the molecular pathways involved in fibroblast activation and extracellular matrix remodeling, particularly in the context of pulmonary fibrosis. She is skilled in utilizing genetically modified mouse models, primary cell culture, 3D organoids, and precision-cut lung slices (PCLS) to explore disease mechanisms. Dr. Rahar also has strong interests in inflammation biology, hypoxia responses, and biomarker discovery, as demonstrated in her previous research on high-altitude hypoxia and peptide-based immune regulation. She aims to translate basic science discoveries into targeted therapies that improve diagnostic accuracy and therapeutic outcomes. Her long-term vision is to bridge the gap between lab research and clinical application, making significant contributions to personalized medicine, especially in chronic respiratory and inflammatory disorders. Her interdisciplinary focus equips her to tackle complex biomedical questions with clinical relevance.

Award and Honor

Dr. Babita Rahar has received numerous academic and research recognitions that highlight her commitment to scientific excellence. In 2025 and 2024, she earned multiple Best Poster Awards at prestigious research events hosted by the University of Wisconsin–Madison, along with a Postdoctoral Mentorship Award and a Travel Award from the Department of Medicine. Earlier, she was awarded the Senior and Junior Research Fellowships by the University Grants Commission (UGC) of India—highly competitive honors that supported her doctoral studies. Dr. Rahar also successfully qualified elite national-level examinations including CSIR-NET, GATE, JAM, and the JNU-DBT exam, all of which are considered benchmarks of academic distinction in India. Her academic achievements began early, earning the Gargi Award for academic excellence during her school years. These accolades reflect not only her scientific competence but also her consistency, leadership potential, and impactful contributions across multiple stages of her academic and professional career.

Conclusion

Dr. Babita Rahar is a dynamic and accomplished biomedical researcher with a strong foundation in molecular biology and translational medicine. Her educational and professional journey reflects exceptional dedication to advancing research in pulmonary diseases and immune modulation. With a robust publication record, advanced technical expertise, and cross-continental research experience, she stands out as a well-rounded scientist committed to bridging basic science and clinical application. Her work is both impactful and collaborative, contributing significantly to the understanding of complex disease mechanisms such as fibrosis and inflammation. Recognized with multiple awards and fellowships, Dr. Rahar embodies the values of innovation, leadership, and scientific rigor. She is well-positioned to make substantial future contributions to biomedical research and is a highly suitable candidate for recognition through awards such as the Best Researcher Award. Her ongoing efforts are likely to lead to novel therapeutic strategies and improved patient outcomes in critical areas of healthcare.

Publications Top Notes

  • Title: S1P prophylaxis mitigates acute hypobaric hypoxia‐induced molecular, biochemical, and metabolic disturbances: A preclinical report

    • Authors: S. Chawla, B. Rahar, S. Saxena

    • Year: 2016

    • Citations: 20

  • Title: Preventive preclinical efficacy of intravenously administered sphingosine-1-phosphate (S1P) in strengthening hypoxia adaptive responses to acute and sub-chronic hypobaric hypoxia

    • Authors: S. Chawla, B. Rahar, R. Tulswani, S. Saxena

    • Year: 2020

    • Citations: 17

  • Title: Exogenous sphingosine-1-phosphate boosts acclimatization in rats exposed to acute hypobaric hypoxia: assessment of haematological and metabolic effects

    • Authors: S. Chawla, B. Rahar, M. Singh, A. Bansal, D. Saraswat, S. Saxena

    • Year: 2014

    • Citations: 17

  • Title: Sphingosine-1-phosphate pretreatment amends hypoxia-induced metabolic dysfunction and impairment of myogenic potential in differentiating C2C12 myoblasts by stimulating …

    • Authors: B. Rahar, S. Chawla, S. Pandey, A.N. Bhatt, S. Saxena

    • Year: 2018

    • Citations: 13

  • Title: [64Cu]Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis

    • Authors: H.J. Lee, K. Bernau, T.J. Harr, Z.T. Rosenkrans, G.A. Kessler, K. Stott, A.T. Oler, B. Rahar, et al.

    • Year: 2024

    • Citations: 7

  • Title: Characterization of immune responses associated with ERAP-1 expression in HSV-induced Behçet’s disease mouse model

    • Authors: H.M. Ryu, S.M.S. Islam, H.M. Sayeed, B. Rahar, J.K. Seong, H. Lee, S. Sohn

    • Year: 2023

    • Citations: 7

  • Title: Acute hypobaric hypoxia-mediated biochemical/metabolic shuffling and differential modulation of S1PR-SphK in cardiac and skeletal muscles

    • Authors: B. Rahar, S. Chawla, R. Tulswani, S. Saxena

    • Year: 2019

    • Citations: 5

  • Title: The fibronectin-targeting PEG-FUD imaging probe shows enhanced uptake during fibrogenesis in experimental lung fibrosis

    • Authors: T.J. Harr, N. Gupta, B. Rahar, K. Stott, Y. Medina-Guevara, M.K. Gari, A.T. Oler, et al.

    • Year: 2025

    • Citations: 1

  • Title: PEG-FUD, A Promising Probe for Pulmonary Fibrosis, Targets the Pro-fibrotic Phase of Disease

    • Authors: K. Bernau, T.J. Harr, N. Gupta, K. Stott, B. Rahar, A.T. Oler, Y. Medina-Guevara, et al.

    • Year: 2024

    • Citations: 1